Results 251 to 260 of about 38,837 (270)

Ethnic differences in the comparative effectiveness of second‐line type 2 diabetes medications in preventing cardiovascular disease

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1013-1023, February 2026.
Abstract Aim To investigate ethnic differences in the comparative effectiveness of sulfonylureas (SU), dipeptidyl peptidase‐4 inhibitors (DPP4i) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) on cardiovascular outcomes. Materials and Methods We identified adults with type 2 diabetes in UK electronic health records initiating SU, DPP4i or SGLT2i
Mia Harley   +7 more
wiley   +1 more source

Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists for incident dementia: A retrospective multicohort study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1443-1452, February 2026.
Abstract Objective This study provides real‐world evidence on the comparative effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) regarding the risk of incident dementia in adults with type 2 diabetes mellitus (T2DM).
Filippos Anagnostakis   +4 more
wiley   +1 more source

Enantioconvergent Access to Chiral S(VI) Stereocenters by Kinetic Resolution of Sulfonimidoyl Chlorides

open access: yesAngewandte Chemie, Volume 138, Issue 2, 9 January 2026.
An enantioconvergent approach for the kinetic resolution of S(VI) stereocenters that leverages the electrophilic reactivity of the chiral sulfur atom is described. The catalytic process provides access to sulfonimidoyl chlorides and sulfonimidates, which are among the least studied S(VI) functionalities.
Arko Das   +10 more
wiley   +2 more sources

Polypharmacy in HIV: Rethinking what counts and why it matters

open access: yesHIV Medicine, Volume 27, Issue 2, Page 186-199, February 2026.
Abstract Polypharmacy, the concurrent use of multiple medications, presents a growing challenge in HIV care as people living with HIV age and experience earlier onset of age‐related co‐morbidities. However, how polypharmacy is defined and assessed in HIV research remains inconsistent.
Luxsena Sukumaran   +6 more
wiley   +1 more source

Comorbidities in People With Intellectual Disability With and Without Schizophrenia and Schizophrenia Without Intellectual Disability: A Swedish Register Study (IDcare)

open access: yesJournal of Intellectual Disability Research, Volume 70, Issue 2, Page 206-217, February 2026.
ABSTRACT Background Intellectual disability (ID) and schizophrenia are known to separately carry a high risk of comorbidity of mental health and physical conditions. However, the prevalence and risk of comorbidities among people diagnosed with concurrent ID and schizophrenia have to date not been studied.
Trine Lise Bakken   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy